Mumbai-based OmniActive Health Technologies has strategically entered the burgeoning women’s health sector with the launch of Fenavari, a novel combination ingredient featuring shatavari and fenugreek, rigorously supported by a placebo-controlled clinical trial. This launch marks a significant step for the company, leveraging the increasing consumer and scientific interest in natural solutions for women’s physiological well-being, particularly during menopausal transitions.
The Science Behind Fenavari: A Synergistic Botanical Blend
Fenavari represents a carefully formulated hydroethanolic extract, meticulously balanced in a three-to-one ratio of shatavari roots (Asparagus racemosus) to fenugreek seeds (Trigonella foenum-graecum). This precise composition is designed to harness the synergistic properties of these two ancient Ayurvedic botanicals, both of which have a long-standing tradition of use in supporting women’s health. The ingredient is standardized to deliver key bioactive compounds: 6% Shatavarin-IV, a prominent steroidal saponin found in shatavari, and 4% Protodioscin, another significant steroidal saponin derived from fenugreek. These compounds are believed to be instrumental in the observed health benefits.
The development of Fenavari is underpinned by a robust clinical study, the findings of which have been formally published in the esteemed journal Women’s Health Reports. This scientific validation is crucial in a market increasingly demanding evidence-based products. The study, a randomized, placebo-controlled, three-arm clinical trial, was conducted across multiple research centers in India, involving 150 participants. The participants were women aged between 40 and 60 years, experiencing at least two daily symptoms indicative of menopause or perimenopause. These common symptoms included hot flashes, headaches, mood swings, and sleep disturbances. The study cohort was diverse, encompassing generally healthy women across a spectrum of body compositions, from slender to obese, to ensure the findings were broadly applicable.
Participants were instructed to maintain their regular daily routines concerning diet and exercise throughout the 12-week trial, minimizing external variables that could influence the results. The trial design allocated participants into three distinct groups: one receiving a daily dosage of 300 mg of Fenavari, a second group receiving a higher daily dose of 500 mg, and a control group receiving a placebo.
The efficacy of Fenavari was evaluated using the Menopause Rating Scale (MRS), a well-established and standardized measurement tool first developed in the 1990s. The MRS assesses menopausal symptoms across somatic (physical), psychological, and vasomotor (hot flashes, night sweats) domains, providing a comprehensive and objective measure of symptom severity. Secondary endpoints of the study included evaluating changes in sleep quality, mood states, the incidence of hot flashes and/or night sweats, and other relevant health indicators.
The study’s conclusions were highly encouraging. The authors reported that Fenavari demonstrated a significant improvement in menopausal symptoms across all assessed domains, commencing as early as Day 14 of the trial. Furthermore, the ingredient was found to positively impact sleep quality, reduce anxiety, improve mood, and even show favorable hormonal changes. Crucially, the study reported no adverse events that could be attributed to either dosage of Fenavari, suggesting a favorable safety profile for the ingredient.
Strategic Positioning in a Thriving Market
OmniActive Health Technologies is positioning Fenavari not merely as another botanical supplement but as a scientifically validated, integrated solution designed to address the multifaceted needs of women navigating the menopausal journey. Keya Shah, Senior Director of the Women’s Health Category at OmniActive, emphasized this point, stating, "Shatavari may be trending, but both shatavari and fenugreek have a long history of use in women’s health. Fenavari harnesses the power of both botanicals in one clinically studied, integrated extract, giving brands and doctors a natural solution for the full menopausal journey." This highlights the company’s strategy to offer a differentiated product backed by robust scientific data.
A Favorable Climate for Women’s Health Innovations
The launch of Fenavari arrives at a propitious moment, as several converging trends are fueling unprecedented growth and interest in the women’s health sector. Steve Hanson, founder and CEO of the consulting firm Nutrasocial, observes that the category, particularly concerning perimenopause and menopause, has transitioned from a latent market to a significant and actively growing segment. "The real focus on perimenopause and menopause has become a significant category in women’s health. That market has been out there but until recently it has been latent," Hanson told SupplySide Supplement Journal. He further noted, "Now there are real options out there and female consumers are purchasing these products."
This heightened consumer demand is paralleled by a growing appreciation for adaptogenic herbs, a trend that has gained considerable momentum over the past decade. While ashwagandha (Withania somnifera) has often been the flagship of this movement, other herbs like shatavari have also benefited from this increased interest. Hanson underscores that this surge in demand is fundamentally consumer-driven. "But make no mistake, this is being driven by consumer demand," he concluded.
The complexity of botanical ingredients and the need for reliable sourcing and formulation are also critical factors in this market. Scott Steinford, CEO of contract manufacturer PreMark Health Sciences, points out the advantages of partnering with established, branded ingredient suppliers like OmniActive. "These botanicals tend to be hard to assay, and that was one of the things that played into this space in the early years when the women’s health category flew under the radar," Steinford commented. He stressed the importance of collaboration between ingredient manufacturers and contract manufacturers to ensure proper dosing and effective formulations, particularly given the historical challenges in accurately characterizing botanical materials. "It’s important for the ingredient manufacturer and the contract manufacturer to be able to work together to determine proper dosing and effective formulations," he advised. Steinford concluded, "OmniActive has been an excellent representative in that regard," acknowledging the company’s commitment to quality and scientific rigor.
Historical Context and Future Implications
The use of shatavari and fenugreek in traditional medicine systems, particularly Ayurveda, dates back centuries. Shatavari, often referred to as the "queen of herbs," has been traditionally used to support reproductive health, lactation, and as an adaptogen to help the body cope with stress. Fenugreek, on the other hand, has a long history of use for digestive health, blood sugar management, and notably, for supporting women’s hormonal balance and lactation. The contemporary scientific validation of these traditional uses is fueling their resurgence in the global supplement market.
The growing scientific interest in the specific compounds within these botanicals, such as Shatavarin-IV and Protodioscin, further strengthens their position. Research is actively exploring the mechanisms by which these steroidal saponins may influence hormonal pathways, potentially impacting symptoms associated with menopause, such as estrogenic activity and effects on the hypothalamic-pituitary-adrenal (HPA) axis.
The introduction of Fenavari by OmniActive is likely to have several implications for the women’s health market. Firstly, it provides formulators and brand owners with a well-researched, standardized ingredient, reducing the variability often associated with botanical extracts and simplifying product development. Secondly, by offering a single, integrated ingredient, it potentially streamlines formulations and marketing claims for finished products. This can empower consumers to make more informed choices, relying on the scientific backing of Fenavari.
Moreover, the success of Fenavari could stimulate further research and development into other synergistic botanical combinations for women’s health. As consumer demand for natural and effective solutions continues to rise, companies that invest in clinical validation and transparent sourcing are poised to gain a significant competitive advantage.
The market for women’s health supplements is projected to continue its upward trajectory. Reports from market research firms consistently indicate robust growth driven by an aging global population, increased awareness of preventative health, and a growing willingness among women to invest in their well-being. OmniActive’s strategic move with Fenavari aligns perfectly with these market dynamics, positioning them to capitalize on this significant and expanding opportunity. The company’s emphasis on clinical evidence and the scientific profiling of their ingredients sets a precedent for innovation in this vital sector of the health and wellness industry.
